Adjuvant endocrine therapy (AET) roughly halves the risk of recurrence among the two-thirds of premenopausal breast cancer patients whose tumors over-express the estrogen receptor (i.e., estrogen receptor positive [ER+]) [1, 2]. The gene discussed is ESR1; the disease is breast carcinoma.